← All trials
NCT04688788
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2021
- Primary completion
- Jan 15, 2025
- Completion date
- Jan 15, 2028
- First posted
- Dec 30, 2020
- Last posted
- Dec 30, 2020
- Enrollment
- 594
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of CopenhagenLead sponsor
- University of CopenhagenOverall official - principal investigator
- Aarhus UniversityCollaborator
- University of CopenhagenCollaborator
- University of Southern DenmarkCollaborator
- University of CopenhagenCollaborator
- University of CopenhagenReponsible party - principal investigator
- Region SyddanmarkCollaborator
- Aalborg UniversityCollaborator
- Danske RegionerCollaborator
- Hospital of Central Denmark Region, Viborg, DenmarkCollaborator
- Central Jutland Regional HospitalCollaborator
- Hospital of South West JutlandCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.